

August 13, 2018

Listing Department  
**BOMBAY STOCK EXCHANGE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code: **532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: **CADILAHC**

Re.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations")

Dear Sir,

We would like to inform that the Company has entered into an agreement to invest in the equity shares of Windlass Healthcare Private Limited (Windlass), for acquiring 51% share capital of Windlass.

The details as required under regulation 30 of the SEBI Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is annexed at **Annexure A** to this letter.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**

Encl.: As above



**Annexure-"A"**  
**Agreement to Acquire Shares**

Sr. No.	Details of events that need to be provided	Information of such event
1.	Name of the target entity, details in brief as size, turnover etc.	Windlas Healthcare Private Limited (WHPL) Sales (FY18)-Rs.33.31 Crore PAT (FY18)-(Rs.5.37 Crore)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	This transaction does not constitute a related party transaction. None of the promoters or group companies of Cadila Healthcare Ltd. have any interest in the entity being acquired.
3.	Industry to which the entity being acquired belongs.	WHPL is engaged in the business of pharmaceuticals.
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	Objective of this investment is to expand pharma manufacturing footprint.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	No regulatory approvals are required for the acquisition.
6.	Indicative time period for completion of the acquisition.	The acquisition will be completed by end of September 2018.
7.	Nature of consideration-whether cash consideration or share swap and details of the same.	The consideration will be paid through cash.
8.	Cost of acquisition or the price at which the shares are acquired.	The cost of acquisition is Rs.155.55 Crore.



Sr. No.	Details of events that need to be provided	Information of such event
9.	Percentage of shareholding / control acquired and/or number of shares acquired.	51% of (post issue) equity share capital will be acquired in WHPL.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Windlas Healthcare Private Limited Date of Incorporation: 12 <sup>th</sup> Feb, 2010 Last three Years turnover: FY18 – Rs.33.31 Crore FY17 – Rs. 27.67 Crore FY16 – Rs.29.12 Crore Country: India

For, CADILA HEALTHCARE LIMITED



**UPEN H. SHAH**  
**COMPANY SECRETARY**

